OncoMed Highlights Immuno-Oncology Discoveries During 2015

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
OncoMed Highlights Immuno-Oncology Discoveries During 2015 Research & Development Day

REDWOOD CITY, Calif., April 29, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq: OMED ), today presented new discoveries related to the company's anti-cancer immuno-oncology pipeline during the company's first Research and Development (R&D) Day for analysts and investors.

"OncoMed has always been focused on developing transformative anti-cancer therapeutics, and the drug discovery efforts we apply to every program have led us to identify some truly first-in-class candidates targeting fundamental cancer stem cell and immuno-oncology pathways," said Paul J. Hastings, OncoMed's Chairman and Chief Executive Officer. "During today's R&D Day event, we showcased the clinical, translational medicine and research science taking place at OncoMed, unveiled emerging programs that haven't yet been in the spotlight, and provided an in-depth understanding of the way we think about drug discovery and development across our portfolio."

Among the highlights of OncoMed's R&D Day were data from a series of experiments that identified a novel immune therapy mechanism for demcizumab (anti-DLL4, OMP-21M18) and demonstrated synergistic activity when anti-DLL4 is combined with an anti-PD1 checkpoint inhibitor. Anti-DLL4 modulates T-cell response by reducing the accumulation of monocytic myeloid-derived suppressor cells, a key population of immunosuppressive cells that inhibit anti-tumor immune responses that are otherwise not addressed by anti-PD1 therapy. When anti-DLL4 is combined with anti-PD1, researchers observed increased inhibition of tumor growth and more robust anti-tumor immune responses in immunocompetent xenograft models as compared to either agent alone. Further, the combination of anti-DLL4 and anti-PD1 reduced tumor growth in re-implantation experiments. These results indicate that dual targeting of DLL4 and PD1 may promote effective and durable cancer therapy by increasing anti-tumor immune response and long-term immunological memory. This research could provide the foundation for a novel clinical development strategy. These data were recently presented at the American Association of Cancer Research (AACR) Annual Meeting.

A new approach, discovered by OncoMed researchers, to inhibit a known immune-oncology receptor was also disclosed publicly for the first time. GITR, a member of the tumor necrosis factor family, is known to be an important receptor in T-cell activation and regulation. OncoMed scientists have devised a novel strategy for the creation of robust T cell activating agents that utilizes fully human single-gene GITRL trimeric ligand attached to an antibody framework. The unique design of OncoMed's proprietary strategy also enables the creation of novel bispecific agents. In preclinical studies, OncoMed's GITRL-Fc candidate results in a potent anti-tumor immune response.

A third example of OncoMed's immuno-oncology research efforts revealed the discovery of a novel and previously "missing" checkpoint target. Tumor cells are believed to take advantage of the immune system's so called "checkpoints" to escape detection. While significant advances have been made in the understanding of checkpoint inhibitors, a number of orphan targets exist and these have been the subject of extensive research by OncoMed scientists for several years. One outcome of these efforts is discovery of a receptor (nicknamed "PD2"), which appears to be an activating receptor for the known checkpoint inhibitor PD-L2. Initial research by OncoMed demonstrates that "PD2" mediates important immunological functions associated with PD-L2. Activation of PD-L2 may provide an entirely new pathway by which to engage the body's own immune system in combatting tumor cells.

In addition, OncoMed's 2015 R&D Day included presentations of recently updated clinical data for demcizumab and tarextumab (anti-Notch2/3, OM59R5) that represent the foundation for the company's four ongoing randomized Phase 2 clinical trials. Additionally, clinical and preclinical proof-of-concept data were presented for two of the company's biomarker assays in development, and overview of OncoMed's approach to elucidating cancer biology to identify and validate new leads and inform clinical trial design.

OncoMed's 2015 R&D Day also featured special guest speakers. Manuel Hidalgo, MD, PhD, Vice Director of Translational Research, Spanish National Cancer Research Centre (CNIO), shared his experience as an investigator in the company's demcizumab clinical trials in pancreatic cancer. Jorge DiMartino, MD, PhD, Vice President, Translational Development of Celgene Corporation provided a presentation on Celgene's multi-product collaboration with OncoMed and the research that initially piqued Celgene's interest.

A webcast of the R&D Day presentations can be accessed under the Investor Relations section of the company's website ( www.oncomed.com ). A replay of the webcast will be archived on the OncoMed website for approximately 60 days following the presentation.

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel therapeutics targeting cancer stem cells (CSCs). OncoMed has six anti-cancer product candidates in clinical development, the most advanced of which are in randomized Phase 2 clinical trials. Demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), brontictuzumab (anti-Notch1, OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), and ipafricept (FZD8-Fc, OMP-54F28) each target key cancer stem cell signaling pathways including Notch and Wnt. OncoMed recently filed an Investigational New Drug application for anti-RSPO3 (OMP-131R10), an antibody targeting a third key cancer stem cell signaling pathway called R-spondin-LGR. OncoMed is also pursuing discovery of additional novel anti-CSC and cancer immuno-oncology product candidates. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). Additional information can be found at the company's website: www.oncomed.com .

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding OncoMed Pharmaceuticals, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including OncoMed ' s expectations regarding the possibility of the dual targeting of DLL4 and PD1 to promote effective and durable cancer therapy by increasing anti-tumor immune response and promoting long-term immunological memory and to provide the foundation for a novel clinical development strategy; and the possibility of PD-L2 and/or its receptor providing a new pathway by which to engage the body ' s own immune system in combatting tumor cells. Such forward-looking statements involve substantial risks and uncertainties that could cause OncoMed ' s clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the preclinical and clinical development process; the risks and uncertainties of the regulatory approval process; OncoMed ' s dependence on its collaboration partners, including Celgene, GSK and Bayer, for the funding of its partnered programs; OncoMed ' s ability to raise additional capital to support the development of its unpartnered programs; OncoMed ' s dependence on the development and marketing efforts of its partners for the commercial success of its partnered product candidates; OncoMed ' s reliance on third parties to conduct certain preclinical studies and all of its clinical trials; OncoMed ' s reliance on single source third-party contract manufacturing organizations to manufacture and supply its product candidates; OncoMed ' s ability to validate, develop and obtain regulatory approval for companion diagnostics; OncoMed ' s ability to achieve market acceptance and commercial success of its product candidates once regulatory approval is achieved; OncoMed ' s ability to discover, develop and commercialize additional product candidates; the ability of competitors to discover, develop or commercialize competing products more quickly or more successfully; OncoMed ' s dependence on its Chairman and Chief Executive Officer, its Chief Scientific Officer, its Chief Medical Officer and other key executives; risk of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate OncoMed ' s patents or proprietary rights; and the ability of OncoMed ' s proprietary rights to protect its technologies and product candidates. OncoMed undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to OncoMed ' s business in general, see OncoMed's Annual Report on Form 10-K for the fiscal year ended December 31, 2014, filed with the Securities and Exchange Commission (SEC) on March 12, 2015.

Media & Investors OncoMed Pharmaceuticals Michelle Corral Senior Director, Investor Relations and Corporate Communications (650) 995-8373 Investors Shari Annes Annes Associates (650) 888-0902

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 518

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 530

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 45

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading

Top 5 Most Recently Viewed Articles

Eaton Corp's Options Trading Insights and Market Analysis

Updated Category News Views 116

Understanding Eaton Corp's Options Trading Trends Recently, financial analysts have noticed a significant bearish trend when it comes to options trading for Eaton Corp (NYSE: ETN). Investigating the history of options trades has revealed insights into the market sentiment surrounding this industrial giant. A thorough analysis showed that a mere 11% of traders exhibited...

Continue Reading
Celebrating Community Resilience After Pacific Palisades Fires

Updated Category News Views 207

Community Resilience Shines in Pacific Palisades The recent reopening of the Casa Gateway affordable housing complex in Pacific Palisades brings a heartwarming sense of relief to many residents who faced the devastating impact of fires. Amidst the recovery efforts, stories of gratitude and hope shine through, demonstrating the importance of community support and...

Continue Reading
Stellantis Makes Bold Move with $41 Million Investment for Efficiency

Updated Category News Views 225

Stellantis Invests $41 Million for Enhanced Parts Delivery Stellantis (NASDAQ: STLA), the parent organization of popular automotive brands such as Jeep and Dodge, is taking significant steps towards improving its logistics capabilities with a substantial $41 million investment. This financial commitment is part of a broader strategy to modernize its parts distribution...

Continue Reading
Navigating the Shifts in Money Market Dynamics and Bank Reserves

Updated Category News Views 137

Understanding Current Dynamics in Money Markets The landscape of liquidity in the money markets is currently characterized by ample conditions. However, experts anticipate a reduction in bank reserves in the months ahead, leading to a potential tightening of conditions. With ongoing activity in market repurchase agreements (repo) and a robust issuance of treasury bills,...

Continue Reading
Harnessing AI and Human Intelligence for Personal Growth

Updated Category News Views 329

AI Happiness Accelerator Empowers Personal Growth Imagine if you could optimize your thoughts and emotions just like improving a website’s performance. The AI Happiness Accelerator (AHA) aims to do exactly that by leveraging cutting-edge Generative AI tools. Co-founder and Chief Information Officer Amy Chang emphasizes that success in all areas—personal, relational,...

Continue Reading